SCHEMBL3102189

SCHEMBL3102189

O=C(NCc1nc(-c2ccc(Br)cc2)c(-c2ccc(Cl)cc2Cl)cc1CNC(=O)c1ccc(SC(F)(F)F)cc1)Nc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNK2 O95069 4/20 0.39
KCNK10 P57789 4/20 0.39
CNR1 P21554 5/20 0.38
NAMPT P43490 1/20 0.36
MET P08581 1/20 0.36
KDR P35968 1/20 0.36
MAPT P10636 3/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
GCG P01275 1/20 0.35
GCGR P47871 1/20 0.35
SCN2A Q99250 1/20 0.35
SCN10A Q9Y5Y9 1/20 0.35
CNR2 P34972 1/20 0.35
LMNA P02545 1/20 0.35
EPHX2 P34913 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3658814 0.91 KCNK2 (0.41) KCNK2KCNK10CNR1MEN1KMT2A
SCHEMBL3102247 0.88 CNR1 (0.39) KCNK2KCNK10CNR1KMT2AGCG
SCHEMBL3114225 0.88 DDR1 (0.38) KCNK2KCNK10CNR1MEN1KMT2A
SCHEMBL3113811 0.87 KCNK2 (0.40) KCNK2KCNK10CNR1MEN1KMT2A
SCHEMBL3115945 0.87 KCNK2 (0.39) KCNK2KCNK10CNR1MAPTMEN1
SCHEMBL3110314 0.86 DDR1 (0.38) KCNK2KCNK10CNR1KMT2ASMN1; SMN2
SCHEMBL3111589 0.85 ROCK2 (0.36) KCNK2KCNK10CNR1GCGGCGR
SCHEMBL3103535 0.85 KCNK2 (0.39) KCNK2KCNK10LMNAEPHX2
SCHEMBL3116597 0.85 KCNK2 (0.40) KCNK2KCNK10KMT2AGCGGCGR
SCHEMBL3106166 0.84 DDR1 (0.36) KCNK2KCNK10CNR1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362045-B2 5,6-diaryl pyridines substituted in the 2- and 3-position, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-01-29 US disclosed
US-20100256202-A1 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-10-07 US disclosed
EP-2209768-A1 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2010-07-28 EP disclosed
WO-2009087285-A1 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256202-A1 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF ALK, ROS1, CYP11B2 KCNK2 651/4885KCNK10 1487/4885CNR1 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.